Executive Summary: Key Takeaways from HBN’s港股IPO Filing
– HBN, a Chinese功效skincare brand, has submitted its港股IPO application, reporting revenues of 1.5 billion yuan in the first nine months of 2025, with net profit surging 190.3% year-over-year.
– The brand pioneered the “早C晚A” (morning Vitamin C, evening Retinol) skincare trend, accumulating over 4.6 million复购users and achieving复购rates of 35.4% on Tmall and 44% on Douyin, well above industry averages.
– Despite strong profitability, HBN faces challenges with high marketing依赖, as sales and distribution expenses accounted for 57.6% of revenue in 2025, while研发投入 declined to 2.6% of revenue.
– Corporate governance aspects include founder Yao Zhenan (姚哲男) and his spouse controlling 76.19% of voting rights, and a pre-IPO dividend payout of 1 billion yuan, raising questions about capital allocation.
– HBN’s港股IPO is part of a broader trend of Chinese beauty brands listing in Hong Kong, driven by flexible regulations and南向资金, but efficacy claims and regulatory compliance remain critical hurdles.
The Rise of HBN: From Niche Brand to港股IPO Contender
The Chinese skincare market has witnessed a seismic shift with the “国货崛起” (rise of domestic brands) movement, transforming from mere slogan to tangible reality. As this wave crests into capital markets,功效skincare brand HBN has emerged as a frontrunner, filing for a港股IPO that could redefine its trajectory from viral sensation to enduring powerhouse. HBN’s港股IPO represents not just a corporate milestone but a litmus test for the sustainability of China’s beauty innovators in an increasingly competitive landscape. With revenues hitting 1.5 billion yuan in early 2025 and a loyal base of affluent consumers, this move signals confidence yet underscores the delicate balance between growth and governance.
Financial Foundations: Steady Revenue and Explosive Profit Growth
HBN’s financial performance, as detailed in its招股书 (prospectus), showcases a brand in rapid ascent. Revenue climbed from 1.948 billion yuan in 2023 to 2.083 billion yuan in 2024, with the first nine months of 2025 reaching 1.514 billion yuan—a 10.2% increase year-over-year. More impressively, profitability has skyrocketed: net profit jumped from 39 million yuan in 2023 to 129 million yuan in 2024, a 232.5% surge, and further rose to 145 million yuan in the first three quarters of 2025, up 190.3%. This profit growth outpacing revenue highlights operational efficiency gains, with net profit margin expanding from 1.9% in 2023 to 9.6% in 2025. Gross margins have remained robust at around 75%, indicating strong pricing power and cost control, akin to premium global peers. However, the path to HBN’s港股IPO is paved with both promise and peril, as these figures mask deeper structural dependencies.
Cash Flow and Operational Health: The Lifeblood of Expansion
The “早C晚A” Phenomenon: HBN’s Market Differentiation EngineHBN’s ascent is inextricably linked to its early adoption of the “早C晚A” skincare philosophy—using Vitamin C products in the morning for antioxidant protection and Retinol at night for anti-aging repair. This concept, which gained viral traction on social media platforms like小红书, catapulted HBN into the spotlight. By 2019, HBN was among the first domestic brands to commercialize this trend, leveraging its expertise in视黄醇 (Retinol) formulation. The strategy paid off handsomely: flagship products such as the “视黄醇塑颜精华乳” (Retinol Sculpting Essence Milk) and “α-熊果苷焕颜精萃水” (Alpha-Arbutin Revitalizing Essence Water) have led their categories in national sales for three consecutive years (2022-2024), with cumulative sales exceeding 30 million units. This success underscores how HBN’s港股IPO is built on a foundation of trend-setting innovation, but sustaining it requires more than marketing savvy.
Building a Loyal Customer Base: The 4.6 Million复购Users
Operational Challenges: Marketing依赖and the研发DilemmaA critical analysis of HBN’s operations reveals a tension between short-term growth and long-term sustainability. Sales and distribution expenses have consumed a substantial portion of revenue: 65.1% in 2023, 59.4% in 2024, and 57.6% in the first nine months of 2025. While trending downward, this “重营销、轻研发” (heavy marketing, light研发) model raises red flags for investors evaluating HBN’s港股IPO. In contrast,研发投入 has dwindled from 3.4% of revenue in 2023 to 2.6% in 2025, below the 5-10% typical for global skincare leaders. This imbalance could hinder innovation pipeline development, essential for competing in the功效skincare segment where scientific credibility is paramount. HBN’s港股IPO prospectus must address how it plans to recalibrate these investments to foster enduring competitiveness.
Channel Concentration and Offline Expansion Efforts
Corporate Governance and Pre-IPO Moves: Founder Control and DividendsGovernance structures at HBN reflect typical startup dynamics but with implications for post-IPO stability. Founder Yao Zhenan (姚哲男) and his spouse collectively hold 76.19% of voting rights through direct and indirect holdings, including a 48.68% direct stake. This concentration can enable swift decision-making but may raise concerns about minority shareholder protections ahead of HBN’s港股IPO. More notably, the company announced a 1 billion yuan cash dividend prior to its IPO filing, with 560 million yuan already disbursed. Based on ownership, the founders likely received nearly 500 million yuan. While legal, such pre-IPO payouts can be viewed as extracting value before public listing, potentially conflicting with stated goals of using IPO proceeds for business expansion. This move underscores the need for transparent capital allocation strategies as HBN’s港股IPO progresses.
Regulatory Scrutiny and the “真功效” (Real Efficacy) Promise
The港股IPO Wave: Context for HBN’s Listing AmbitionsHBN’s港股IPO is part of a broader surge in Chinese beauty brands seeking listings in Hong Kong. Since “国货彩妆第一股” (first domestic color cosmetics stock)毛戈平 (Mao Geping) debuted on the HKEX in late 2024, peers like林清轩 (Lin Qingxuan) have followed, with珀莱雅 (Proya) and丸美 (Marubi) also advancing IPO plans. This trend is driven by港股’s相对灵活的门槛 (relatively flexible thresholds) and备案制改革 (filing system reforms), which offer clearer paths to capital compared to A股’s stringent审核 (review processes). Additionally,活跃的南向资金 (active southbound capital flows) provide liquidity tailwinds. For HBN’s港股IPO, this environment presents both opportunities and pressures: while access to capital is enhanced, standing out in a crowded field requires demonstrable differentiation in研发and sustainability.
Market Implications and Investor Sentiment
Looking Ahead: Strategic Imperatives for HBN Post-IPOHBN’s港股IPO marks a pivotal chapter, but the journey ahead is fraught with challenges and opportunities. To capitalize on its public listing, the company must address its研发deficit by allocating IPO proceeds toward advanced formulation labs and clinical trials, potentially partnering with institutions like the中国化妆品行业协会 (China Cosmetics Industry Association). Diversifying revenue streams through international expansion and brick-and-mortar partnerships will mitigate online依赖risks. Moreover, enhancing governance transparency—perhaps by appointing independent directors with skincare expertise—could bolster investor trust. As consumers and regulators demand greater accountability, HBN’s commitment to “真功效” must be unwavering, backed by rigorous testing and clear communication.
Investors and industry watchers should closely monitor HBN’s港股IPO process, from pricing to post-listing performance, as it reflects broader trends in Chinese consumer equities. For those considering participation, due diligence on marketing efficiencies, regulatory compliance, and founder alignment with public shareholders is essential. The brand’s ability to evolve from a “网红品牌” (internet-famous brand) to a “长红品牌” (long-lasting brand) will depend on strategic execution beyond the IPO hype. As the Chinese beauty market continues to mature, HBN’s港股IPO serves as a case study in navigating the intersection of innovation, capital, and consumer trust in the dynamic Asian equity landscape.